.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,425,938

« Back to Dashboard

Claims for Patent: 8,425,938

Title:Pharmaceutical composition
Abstract: The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and (b) a rate controlling means comprising a rate-controlling agent and/or a coating selected from (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.
Inventor(s): Zala; Yashoraj Rupsinh (Mumbai, IN), Dharmadhikari; Nitin Bhalachandra (Mumbai, IN)
Assignee: Sun Pharma Advanced Research Company Ltd. (Mumbai, IN)
Application Number:13/102,272
Patent Claims: 1. An oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of a therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and pharmaceutical excipients; and (b) an active ingredient permeable coating surrounding the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet, wherein said unit dosage form is suitable for once-a-day administration, and wherein said levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount equivalent to from about 750 mg to about 1600 mg of levetiracetam.

2. The oral controlled release pharmaceutical composition as claimed in claim 1, wherein the pharmaceutically acceptable excipients are rate controlling agents.

3. The oral controlled release pharmaceutical composition as claimed in claim 2, wherein the rate controlling agent is selected from the group consisting water-soluble hydrophilic polymers, water-insoluble hydrophobic polymers, hydrophobic excipients and mixtures thereof.

4. The oral controlled release pharmaceutical composition as claimed in claim 3, wherein the water soluble hydrophilic polymers are selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, vinyl acetate copolymers, polysaccharides, polyethylene oxide, methacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers and derivatives and mixtures thereof.

5. The oral controlled release pharmaceutical composition as claimed in claim 3, wherein the water-insoluble hydrophobic polymers are selected from the group consisting of acrylates, cellulose derivatives such as ethylcellulose or cellulose acetate, methacrylates, acrylic acid copolymers and high molecular weight polyvinylalcohols and mixtures thereof.

6. The oral controlled release pharmaceutical composition as claimed in claim 3, wherein the hydrophobic excipient is selected from the group consisting of a natural fat, beeswax, polyethoxylated beeswax, a mono-, bi- or tri-substituted glyceride, glycerylpalmitostearate, glycerylbehenate, diethyleneglycolpalmitostearate, a polyethyleneglycol stearate, a polyoxyethyleneglycolpalmitostearate, glycerylmonopalmitostearate, cetylpalmitate, polyethyleneglycolpalmitostearate, mono- or di-glycerylbehenate, a fatty alcohol associated with a polyethoxylate fatty alcohol, cetyl alcohol, stearic acid, a saturated or unsaturated fatty acid or a hydrogenated derivative thereof, and/or hydrogenated castor oil and mixtures thereof.

7. The oral controlled release pharmaceutical composition as claimed in claim 2, wherein the rate-controlling agent is used in an amount ranging from 1 to 20% by weight of the dosage form.

8. The oral controlled release pharmaceutical composition as claimed in claim 1, wherein the active ingredient permeable coating comprises one or more water-soluble polymers, water-insoluble polymers, pH dependent polymers and mixtures thereof.

9. The oral controlled release pharmaceutical composition as claimed in claim 8, wherein water-soluble polymers are selected from the group consisting of methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyethylene glycol, sugars, amino acids, bulking agents such as polydextrose, organic acids or salts thereof, glycerin, glycols, and mixtures thereof.

10. The oral controlled release pharmaceutical composition as claimed in claim 8, wherein the water-insoluble polymers are selected from as water insoluble cellulose derivatives such as ethyl cellulose.

11. The oral controlled release pharmaceutical composition as claimed in claim 8, wherein the pH-dependent polymers are selected from various grades of methacrylic acid copolymers, the different grades being dependent on the methacrylic acid content and the viscosity of the methacrylic acid polymers.

12. The oral controlled release pharmaceutical composition as claimed in claim 9, wherein the water-soluble polymer is hydroxypropyl methyl cellulose and the water insoluble polymer is ethyl cellulose, coated to a weight gain of about 9% by weight of the core.

13. The oral controlled release pharmaceutical composition as claimed in 12, wherein the ratio of ethyl cellulose:hydroxypropyl methyl cellulose is 70:30.

14. The oral controlled release pharmaceutical composition as claimed in claim 10, wherein the water-soluble polymer is hydroxypropyl methyl cellulose and the water insoluble polymer is ethyl cellulose, coated to a weight gain of about 9% by weight of the core.

15. The oral controlled release pharmaceutical composition as claimed in 14, wherein the ratio of ethyl cellulose:hydroxypropyl methyl cellulose is 70:30.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc